The feasibility of pelvic floor training to treat urinary incontinence in women with breast cancer: a telehealth intervention trial.

Show simple item record

dc.contributor.author Colombage, Udari N
dc.contributor.author Soh, Sze-Ee
dc.contributor.author Lin, Kuan-Yin
dc.contributor.author Kruger, Jennifer
dc.contributor.author Frawley, Helena C
dc.coverage.spatial Japan
dc.date.accessioned 2023-03-09T02:13:07Z
dc.date.available 2023-03-09T02:13:07Z
dc.date.issued 2023-01
dc.identifier.citation (2023). Breast Cancer, 30(1), 121-130.
dc.identifier.issn 1340-6868
dc.identifier.uri https://hdl.handle.net/2292/63236
dc.description.abstract <h4>Purpose</h4>To investigate the feasibility of recruiting into a pelvic floor muscle training (PFMT) program delivered via telehealth to treat urinary incontinence (UI) in women with breast cancer on aromatase inhibitors.<h4>Methods</h4>We conducted a pre-post single cohort clinical trial with 54 women with breast cancer. Participants underwent a 12-week PFMT program using an intra-vaginal pressure biofeedback device: femfit<sup>®</sup>. The intervention included eight supervised individual PFMT sessions over Zoom<sup>™</sup> and a 12-week home exercise program. The primary outcome of this study was feasibility, specifically consent rate. Secondary outcomes which included prevalence and burden of UI measured using the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF), and pelvic floor muscle (PFM) strength measured as intravaginal squeeze pressure were compared using McNemar's and paired t tests.<h4>Results</h4>The mean age of participants was 50 years (SD ± 7.3). All women who were eligible to participate in this study consented (n = 55/55, 100%). All participants reported that the program was beneficial and tailored to their needs. The results showed a statistically significant decline in the prevalence (percentage difference 42%, 95% CI 28, 57%) and burden (ICIQ-UI SF score mean change 9.4, 95% CI 8.5, 10.4) of UI post intervention. A significant increase in PFM strength was observed post-intervention (mean change 4.8 mmHg, 95% CI 3.9, 5.5).<h4>Conclusion</h4>This study indicated that PFMT delivered via telehealth may be feasible and potentially beneficial in treating stress UI in women with breast cancer. Further studies such as randomized controlled trials are required to confirm these results.
dc.format.medium Print-Electronic
dc.language eng
dc.publisher Springer Nature
dc.relation.ispartofseries Breast cancer (Tokyo, Japan)
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject Pelvic Floor
dc.subject Humans
dc.subject Breast Neoplasms
dc.subject Urinary Incontinence
dc.subject Treatment Outcome
dc.subject Exercise Therapy
dc.subject Feasibility Studies
dc.subject Telemedicine
dc.subject Quality of Life
dc.subject Middle Aged
dc.subject Female
dc.subject Breast cancer
dc.subject Pelvic floor muscle training
dc.subject Telehealth
dc.subject Cancer
dc.subject Urologic Diseases
dc.subject Clinical Research
dc.subject Prevention
dc.subject Aging
dc.subject Clinical Trials and Supportive Activities
dc.subject Rehabilitation
dc.subject 6.7 Physical
dc.subject 6 Evaluation of treatments and therapeutic interventions
dc.subject Renal and urogenital
dc.subject Reproductive health and childbirth
dc.subject 1112 Oncology and Carcinogenesis
dc.title The feasibility of pelvic floor training to treat urinary incontinence in women with breast cancer: a telehealth intervention trial.
dc.type Journal Article
dc.identifier.doi 10.1007/s12282-022-01405-6
pubs.issue 1
pubs.begin-page 121
pubs.volume 30
dc.date.updated 2023-02-03T22:22:56Z
dc.rights.holder Copyright: The authors en
dc.identifier.pmid 36163601 (pubmed)
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/36163601
pubs.end-page 130
pubs.publication-status Published
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Clinical Trial
pubs.subtype research-article
pubs.subtype Journal Article
pubs.elements-id 920667
pubs.org-id Bioengineering Institute
pubs.org-id ABI Associates
dc.identifier.eissn 1880-4233
dc.identifier.pii 10.1007/s12282-022-01405-6
pubs.record-created-at-source-date 2023-02-04
pubs.online-publication-date 2022-09-26


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics